TTrialPathMatch Me to Trials
← Back to trials
RecruitingHeart Block CompleteHeart Block Second Degree

Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block

Eligible age

16–50 yrs

Accepts

Women

Locations

12 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Few studies are specifically designed to address health concerns that are already relevant during pregnancy. The consequence is a lack of evidence on best clinical practice. This includes mothers and their babies when pregnancy is complicated by an abnormally slow heart rate due to maternal antibody-mediated heart disease in the unborn baby (fetus). Since the late seventies, it has been possible to detect and monitor fetal disease by ultrasound images and to treat selected conditions with pharmaceuticals administered via the mother. To this day, physicians need to make decisions about the management of such pregnancies without evidence from prospective clinical trials on drug efficacy and safety. The SLOW HEART REGISTRY is a multi-centered prospective observational study that will address the knowledge gap to guide future management of high-degree immune-mediated heart block to the best of care. The study seeks to establish an international database of the management and outcome of affected fetuses, to be used to publish information on the results of currently available prenatal care and to evaluate the need for additional research.

Sponsor: The Hospital for Sick Children

You may qualify if…

  • Written informed maternal consent to participate in the Slow Heart Registry
  • High-degree (2nd; 2:1; 2nd-3rd or 3rd degree) AVB diagnosed ≤ 32+0 weeks with or without hydrops
  • Enrollment within maximally 8 days of high-degree AVB diagnosis
  • Positive or pending anti-Ro/La antibody test results at the time of enrollment

You may not qualify if…

  • AVB associated with major CHD (e.g. left atrial isomerism, cc-TGA)
  • AVB with known negative anti-Ro and/or La antibody test result at enrollment
  • 1st degree AVB
  • Sinus bradycardia with normal 1:1 AV conduction
  • Blocked atrial bigeminy (irregular atrial rate with failure of AV conduction of the premature atrial beat)
  • Primary delivery for postnatal treatment
  • Maternal-fetal conditions (other than cardiac NL) associated with high odds of premature delivery or death (e.g. renal failure, significant infectious diseases, major extracardiac anomalies, PROM, etc.)
  • Preexisting maternal mental disorder (e.g. bipolar, mania, severe depression, substance abuse)

Where it's recruiting

Arizona

Phoenix

California

San Francisco

Colorado

Denver

District of Columbia

Washington D.C.

Florida

St. Petersburg

Kansas

Kansas City

Minnesota

Minneapolis

New York

New York

Texas

Houston

Washington

Seattle

Wisconsin

Milwaukee

Source: ClinicalTrials.gov · NCT04559425 · last updated 2024-05-22